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Abstract: Heme is a ubiquitous and essential iron containing metallo-organic cofactor required for 
virtually all aerobic life. Heme synthesis is initiated and completed in mitochondria, followed by 
certain covalent modifications and/or its delivery to apo-hemoproteins residing throughout the 
cell. While the biochemical aspects of heme biosynthetic reactions are well understood, the 
trafficking of newly synthesized heme—a highly reactive and inherently toxic compound—and its 
subsequent delivery to target proteins remain far from clear. In this review, we summarize current 
knowledge about heme biosynthesis and trafficking within and outside of the mitochondria. 
Keywords: mitochondria; heme; porphyrin; heme biosynthesis; membrane transporters; 
hemoproteins 
 
1. Introduction 
Heme b, or iron protoporphyrin IX (Fe-PPIX), is an essential but potentially cytotoxic protein 
prosthetic group and signaling molecule. The paramount importance of this metallocofactor is 
highlighted by the plethora of hemoproteins present in virtually every subcellular compartment that 
fill vital roles within the eukaryotic cell. As a cofactor, heme is essential for mediating gas synthesis, 
storage and transport; electron transfer; and chemical catalysis [1–6]. As a signaling molecule, heme 
binding to a number of cellular factors including transcription factors, kinases, ion channels and 
micro RNA processing proteins [5,7–9] or its catabolism to the signaling molecule, carbon monoxide 
(CO), collectively regulate diverse physiological processes that include oxygen sensing, iron 
homeostasis, the oxidative stress response, mitochondrial respiration and biogenesis, mitophagy, 
apoptosis, circadian rhythms, cell cycle progression and proliferation [1,7,10–19]. Another vital role 
for heme b is to act as a precursor for the synthesis of other heme types important for eukaryotic 
physiology, including hemes c, o and a (Figure 1).  
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Figure 1. Chemical structures of the various heme types in eukaryotes. Starting with the heme b 
precursor (protoheme), heme c is made through covalent attachment to the sulfhydryl moieties of 
either cytochrome c or complex III subunit cytochrome c1; this process is assisted by the cytochrome c 
lyases. Heme a is synthesized from heme b through the sequential action of heme o synthase and 
heme a synthase enzymes, going through the intermediate, heme o. 
All of the aforementioned heme-dependent processes require that heme is dynamically 
mobilized from its site of synthesis on the matrix side of the mitochondrial inner membrane to 
heme-dependent proteins throughout the cell [2,3]. However, since heme is a hydrophobic and 
cytotoxic species [20,21], cells are challenged to mitigate heme toxicity by appropriately regulating 
cellular heme concentration and bioavailability. The concentration of heme is dictated by the relative 
rates of its synthesis and degradation [2,3]. Despite the fact that all of the proteins involved in the 
synthesis and degradation of heme have been structurally characterized to atomic resolution and 
detailed kinetic studies have revealed their mechanisms of action [2,3], our understanding of how 
the relative rates of heme synthesis are regulated remains far from clear. Furthermore, the 
bioavailability of heme is governed by its transport and trafficking; yet, the molecules and 
mechanisms that mediate these processes are poorly understood.  
Herein, we review the “ins and outs” of heme synthesis, trafficking and utilization, both inside 
and outside the mitochondria. In particular, we will first discuss the biosynthesis of heme and how it 
may be regulated to affect heme bioavailability. Next, we will discuss the mechanisms underlying 
how protoheme IX, or heme b, is trafficked and converted to alternative heme types, including 
hemes c, o and a and how it can exit the mitochondria and be mobilized for use in hemoproteins 
throughout the cell. Finally, we discuss the latest approaches and technologies that can be utilized to 
characterize heme transport and trafficking mechanisms. Where appropriate, we will highlight open 
questions regarding heme homeostatic mechanisms. The mobilization of heme for trafficking and 
signaling, of which little is understood, represents a challenging frontier in heme cell biology. A 
better understanding of heme transport is essential for treating numerous diseases associated with 
defects in heme homeostasis, including certain cancers, cardiovascular diseases and 
neurodegenerative disorders [19,22–25]. 
2. Heme Biosynthesis 
Cells mitigate the toxicity of heme in part by coordinating heme synthesis (see Table 1) with 
heme utilization [1]. Animals, fungi and α-proteobacteria make heme via the C4 (Shemin) pathway, 
whereas plants, archaea and other bacteria utilize the C5 (glutamate) pathway [26]. Here, we focus 
on the former, which requires eight enzymes to construct heme from glycine, succinyl-CoA, 
molecular oxygen (O2) and iron (Fe) [12,27,28]. The first and last three enzymes of the heme 
synthesis pathway in animal and fungi are localized to the mitochondria and the remaining four 
enzymes reside in the cytosol. Heme synthesis can therefore be controlled at multiple levels, 
including substrate availability, partitioning of heme synthetic intermediates between the 
mitochondria and cytosol and direct regulation of the heme biosynthetic enzymes [1,29,30] (Figure 
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2). In this section we examine each of the enzymes involved in heme synthesis, focusing on their 
regulation and thus their ability to control heme availability. 
Table 1. Conservation of heme homeostatic factors between yeast, worm and man. 
Heme 
Homeostatic 
Process 
Enzyme Saccharomyces cerevisiae 
Caenorhabditis 
elegans Homo sapiens 
Heme  
Synthesis 
5-aminolevulinic acid 
synthase Hem1 ✖ ALAS1/ALAS2 
Porphobilinogen 
synthase Hem2 ✖ PBGS 
Hydroxymethylbilane 
synthase Hem3 ✖ HMBS 
Uroporphyrinogen 
synthase Hem4 ✖ UROS 
Uroporphyrinogen 
decarboxylase Hem12 ✖ UROD 
Coproporphyrinogen 
oxidase Hem13 ✖ CPOX 
Protoporphyrinogen 
oxidase Hem14 ✖ PPOX 
Ferrochelatase Hem15 fecl-1 FECH 
Heme 
Degradation Heme oxygenase Hmx1 ? Hmox1/Hmox2 
Heme 
Import 
FLVCR2 ✖ ✔ ✔ 
HRG4 ✖ ✔ ✖ 
Heme  
Export 
FLVCR1 ✖ ✖ ✔ 
MRP5 ✖ mrp-5 ABCC5 
Pug1 ✔ ✖ ✖ 
HRG3 ✖ ✔ ✖ 
Heme 
Trafficking 
PGRMC1/2 Dap1 vem-1 PGRMC1/2 
GAPDH Tdh1/2/3 gpd1/2/3/4 GAPDH 
HRG1 ✖ ✔ ✔ 
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Figure 2. Structures and enzymes involved in heme synthesis shown where they are localized. 
Glycine is transported into the intermembrane space of the mitochondria (IMS) through an unknown 
mechanism and is transported across the inner mitochondrial membrane (IMM) by SLC25A38. 
Succinyl-CoA is synthesized within the matrix. Glycine and Succinyl-CoA are condensed into 
5-aminolevulunic acid (5-ALA) by ALA synthase (ALAS). The 5-ALA is transported from the matrix 
to the cytosol by unknown mechanisms, where Porphobilinogen synthase (PBGS) condensates two 
molecules of ALA into porphobilinogen (PBG). Four molecules of PBG are combined to form a linear 
tetrapyrrole hydroxymethylbilane (HMB) by hydroxymethylbilane synthase (HMBS). 
Uroporphyrinogen III (UPgen III) is synthesized from HMB by uroporphyrinogen synthase (UROS). 
Coproporphyrinogen III (CPgenIII) is synthesized from UPG III by uroporphyrinogen decarboxylase 
(UROD). CPgenIII is transported by an unknown mechanism into the IMS. Within the IMS CPgenIII 
is made into protoporphyrinogen IX (PPgen IX) through catalysis by CPgen oxidase (CPOX). Next, 
PPgen IX is oxidized into protoporphyrin IX (PPIX) by PPgen oxidase (PPOX). For the final step PPIX 
is transported into the matrix, where ferrochelatase (FECH) catalyzes the insertion of ferrous iron 
into the porphyrin ring, resulting in heme b. 
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2.1. ALA Production 
The first committed step of heme biosynthesis in non-plant eukaryotes occurs with the 
pyridoxal 5’-phosphate (PLP)-dependent condensation of glycine and succinyl-CoA to form 
aminolevulinic acid (ALA) by ALA synthase (ALAS) in the mitochondrial matrix (Figure 2). ALAS is 
conserved from bacteria to metazoans [31] and is the universal precursor for all tetrapyrroles 
including chlorophylls, cobalamin, siroheme and coenzyme F430 [31,32]. The supply of glycine from 
the cytosol into the matrix of the mitochondria for ALA production likely occurs by passive 
diffusion across the highly porous outer mitochondrial membrane (OMM) and then through the 
inner mitochondrial membrane (IMM) by Solute Carrier (SLC) family 25A38 (Hem25 in yeast) 
[33,34]. In yeast, one secondary glycine transporter, Ymc1 (another SLC family member), has been 
determined, but it is currently not known whether this protein has a homolog in humans [35]. The 
other ALAS substrate, succinyl-CoA, is synthesized in the mitochondrial matrix, primarily from 
either α-ketoglutarate (α-KG) via α-KG dehydrogenase or succinate via succinyl-CoA synthetase in 
a cell-specific manner [36–39]. 
ALAS structures obtained from α-proteobacterium [40] and yeast [41], both with a high degree 
of sequence homology to the human ALAS core, indicate a tightly bound homodimer. Specifically, 
each monomer consists of three domains that all participate in dimerization: a variable N-terminal 
region, a highly conserved catalytic center with a PLP-lysine Schiff base in the active site and a 
regulatory C-terminal domain. Eukaryotic ALAS proteins contain a cleavable 
mitochondrial-targeting sequence (MTS) at the N-terminus and a well-conserved extension of the 
bacterial C-terminal domain that putatively influences substrate binding [41] and ALA product 
release [42]. Multiple heme regulatory motifs (HRMs) have been identified in the N-terminal domain 
of eukaryotic ALAS, including in the MTS, with the notable exception of yeast [43–45]. Perhaps not 
coincidentally, ALA synthesis is the rate-limiting step in mammalian heme synthesis [28] but not in 
yeast [46].  
Two highly conserved forms of ALAS, ALAS1 and ALAS2 are expressed in mammals [47]. 
ALAS1 is ubiquitously expressed, while ALAS2 is specific to erythroid cells [48]. In nonerythroid 
tissue, feedback inhibition by heme negatively regulates ALAS1 transcription [49], translation 
[50,51], mRNA stability [52], protein stability in the mitochondria [53] and mitochondrial import via 
the MTS [54] to avoid free heme accumulation and toxicity. In contrast, ALAS2, which operates in 
erythroid cells that are obligated to make upwards of ~80 mM heme or ~5 × 109 molecules of heme 
per cell for hemoglobin assembly [55], is not inhibited by heme at any level. ALAS2 synthesis is 
modulated transcriptionally by GATA-1 and other heme-independent factors [56,57] and 
downregulated post-transcriptionally by microRNA [58] and iron regulatory proteins (IRPs) [59]. 
Interestingly, the inhibitory effect of IRP1 and IRP2 via interaction with an ALAS2-specific 5’-iron 
regulatory element (IRE) is abrogated by iron and/or heme [60,61], suggesting that heme could 
indirectly stimulate ALAS2 translation. Unlike in ALAS1, N-terminal HRMs present in ALAS2 
protein do not render mitochondrial import sensitive to heme [54]. Post-translational events that 
impact enzyme activity include the binding of ALAS2 and the AAA+ unfoldase, CLPX, a complex 
which facilitates both PLP binding and ALAS2 degradation [62], as well as hydroxylation of the 
ALAS2 C-terminal extension and the associated proteosomal degradation of the protein [63]. 
2.2. CPgenIII Formation 
After formation of ALA by ALAS, ALA is transported out of the mitochondria back into the 
cytosol by unknown mechanisms (Figure 2). Proposed ALA transporters include SLC25A38 [33]  
and SLC25A39 [64], though these transporters have been implicated in glycine transport [34] and 
iron-sulfur cluster biogenesis [64] and direct evidence of ALA transport via either is lacking. For 
transport of ALA from the IMS to the cytosol, it is possible that ALA may simply diffuse across the 
OMM given the permeability of this membrane to small molecules. Once in the cytosol, ALA is 
converted in four consecutive steps into CPgen III (Figure 2). These steps include condensation of 
two ALA molecules into a single monopyrrole, porphobilinogen (PBG), by the enzyme 
porphobilinogen synthase (PBGS) ((previously known as ALA dehydratase (ALAD)); the 
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head-to-tail synthesis of four PBG molecules to form the linear tetrapyrrole, hydroxymethylbilane 
(HMB), by the enzyme hydroxymethylbilane synthase (HMBS) (previously called porphobilinogen 
deaminase (PBGD)); the spiro inversion and cyclization of HMB to form uroporphyrinogen III by 
uroporphyrinogen synthase (UROS); and the decarboxylation of the four pyrrole acetic acid side 
chains by uroporphyrinogen decarboxylase (UROD) to yield the final product CPgen III and four 
molecules of carbon dioxide [12,65]. In contrast to other eukaryotes, PBGS and HMBS (not ALAS) 
reactions are rate limiting in yeast heme biosynthesis [46]. 
2.3. Coproporphyrinogen Oxidase (CPOX) and Protoporphyrinogen Oxidase (PPOX) 
Once generated, CPgen III is then transported by a currently unknown mechanism into the 
intermembrane space of the mitochondria (IMS) (Figure 2). One study posited that OMM 
ATP-dependent transporter ABCB6 has a role in this process [66]. However this postulate has been 
debated based on the cellular localization of ABCB6 [66,67], with biochemical studies which 
demonstrated binding and transport of porphyrins and not porphyrinogens [66,68,69] and findings 
from animal studies [68,69]. Thus, additional studies are necessary to further investigate the role of 
ABCB6 as a CPgen III transporter in heme synthesis. Once CPgen III is in the IMS, the enzyme 
coproporphyrinogen oxidase (CPOX) converts it to PPgen IX followed by conversion to 
protoporphyrin IX (PPIX) by protoporphyrinogen oxidase (PPOX), a reaction that requires three 
molecules of oxygen and generates three molecules of hydrogen peroxide (H2O2) [12]. A recent study 
employing proximity labeling, mass spectrometry and electron microscopy showed that PPOX 
localizes to the matrix-facing side of IMM [70]. These data suggest that PPgen IX rather than PPIX 
traverses the IMM (Figure 2). The N-terminal moiety of CPOX is anchored in the IMM, so the direct 
transfer via lipid bilayer is one possible scenario. Alternatively, the transfer could involve a 
transporter. It was shown that in yeast, heme and some of its precursors may associate specifically 
with the adenine nucleotide translocator (ANT) and that this binding is inhibited by the ANT 
substrate ADP [71]. Additionally, Azuma et al. [71] found that disruption of the ANT genes in yeast 
(AAC1, PET9 and AAC3) resulted in a reduction of heme biosynthesis via blockage of precursors 
from entering the matrix. These transporters may therefore play certain role in tetrapyrroles 
transport to PPOX and/or FECH. These findings also suggest that ATP:ADP ratios, mitochondrial 
protonmotive force and cellular energy status may regulate heme synthesis in response to changes 
in metabolic demand thus further studies are warranted to elucidate this issue. Another recently 
identified protein which may function in PPgen IX transport is the protein TMEM14C. This protein 
was originally identified in a large-scale gene expression analysis [64] and shown to be important for 
erythropoiesis in zebrafish. Yien et al., [72] expanded these studies and their data demonstrate that 
TMEM14C is important for porphyrin precursor homeostasis thus supporting TMEM14C as a PPgen 
IX transporter. 
2.4. Ferrochelatase 
The final step of heme synthesis involves the insertion of ferrous iron into the PP IX molecule to 
produce protoheme by the enzyme ferrochelatase (FECH or Hem15) on the matrix side of the inner 
membrane (Figure 2). Iron appears to be delivered to FECH via the transporters mitoferrin 1 (MFN1 
or SLC25A37) and mitoferrin 2 (MFN2 or SLC25A28) in mammals [73]. A number of recent 
outstanding reviews focusing on iron delivery to mitochondria can be found elsewhere [74–77]. 
FECH functions by removing two protons from PP IX and inserting Fe2+. Mammalian FECH 
functions as a homodimer where each subunit contains a [2Fe-2S] cluster [78]. While the [2Fe-2S] 
cluster is necessary for enzyme activity [79,80], there is no evidence to support its role in catalysis. 
Work by Shah et al., [81] indicates that it may be serving as a sensor for the redox or membrane 
potential in the mitochondrial matrix. Thus, redox signals may serve to integrate energy metabolism 
with control of heme synthesis.  
Recent biochemical and mass spectrometry-based studies have suggested that the heme 
biosynthetic machinery forms a large complex, termed the mitochondrial heme metabolon [39,82–
84]. Indeed, FECH was found to be a component of a multimeric assembly that included the first and 
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seventh enzymes in the heme synthesis pathway, ALAS and PPOX, respectively. In addition, 
α-ketoglutarate dehydrogenase (KDH) and succinyl-CoA synthase (SUCLA2), which synthesize the 
heme precursor succinyl-CoA, and TMEM14C, a porphyrinogen transporter [39,82], were also 
observed in the complex. Independent studies have also shown mitoferrin, a mitochondrial iron 
importer [84], as well as two ATP binding cassette proteins, ABCB7 [85,86] and ABCB10 [84,86] are 
protein partners of FECH. These results would suggest that substrate channeling and assembly of 
the heme metabolon complex may be a key regulatory node for heme synthesis. Most intriguingly, 
the putative heme chaperones progesterone receptor membrane component 1 (PGRMC1), which has 
been previously proposed to deliver heme to cytochrome P450 enzymes [87–89] and progesterone 
receptor membrane component 2 (PGRMC2), which delivers heme to nuclear heme dependent 
transcription factors in adipose tissue [90] also interacts with FECH [83]. This would suggest that 
certain heme acceptor proteins may interact with the heme metabolon in order to provide an outlet 
valve for heme distribution to other locales. Altogether, FECH may not just be important for heme 
synthesis, but also for mediating heme trafficking and distribution via its interactions with other 
factors. 
Once synthesized, heme is trafficked to other cellular locations, including the matrix, the IMM, 
IMS and any number of extra-mitochondrial locales. However, the molecules and mechanisms that 
mobilize heme from its site of synthesis are not well defined. Recent work supports the role of a 
number of proteins in this distribution, including glyceraldehyde phosphate dehydrogenase 
(GAPDH) [91,92], PGRMC1 [83] and PGRMC2 [90]. Further, it is unclear how the demand for heme 
in different cellular locations regulates the distribution of heme from FECH. 
2.5. Anemias and Porphyrias 
Disorders in heme synthesis can result in pathological conditions in humans. The most common 
of these are the anemias which result from a decrease in the number of circulating erythrocytes 
and/or the amount of hemoglobin in erythrocytes. The most common anemia world-wide is iron 
deficiency anemia in which heme production during erythroid development is limited due to a 
deficiency of iron in the diet. This is particularly problematic in women of child-bearing age in 
third-world countries, since frequent pregnancies deplete body iron stores. Second only to iron 
deficiency are anemias of chronic disease. These anemias result from the body’s inflammatory 
response to infection or disease. A deficiency in ALAS2, the first enzyme in the pathway in erythroid 
precursors, results in sideroblastic anemia [93]. Sideroblastic anemia is characterized by iron 
accumulation in mitochondria and diminished erythroid cell development. In the case of ALAS2 
mutations, iron is available, but heme synthesis is limited. 
The disorders known as the porphyrias are caused by aberrant heme synthesis and the 
concomitant buildup of cytotoxic intermediates in hepatic and/or erythroid tissue. These 
intermediates may produce symptoms of acute neurological dysfunction and/or cutaneous 
photosensitivity [94]. Mutations have been identified in all enzymes of the heme biosynthetic 
pathway except ALAS1 (see reference [93] for comprehensive review). Interestingly induction of 
ALAS1 in liver resulting from elevated heme oxygenase activity [95], consumption of xenobiotics 
[96] or steroids [97] and poor nutrition [98] can precipitate acute porphyric attacks. The most 
recently discovered porphyria is X-linked protoporphyria, which results from gain-of-function 
mutations in ALAS2 [99]. This porphyria resembles erythropoietic protoporphyria, which is caused 
by decreased FECH activity. This phenotype similarity points to metal chelation by FECH as a 
second regulatory step in heme synthesis and hints at some level of regulatory coordination between 
the first and last steps of the pathway. 
At present, there are idiopathic anemias and porphyrias for which no underlying molecular 
cause has been identified. The identification of the multi-protein mitochondrial heme metabolon and 
other protein partners of heme biosynthesis enzymes opens a black box that in time may shed light 
on additional means of heme synthesis regulation. Clearly any mutations in these interacting 
proteins that cause dysfunction in heme synthesis may contribute to porphyrias and anemais. One 
example is a recently discovered CLPX mutation, which has been implicated in porphyria [62]. 
Cells 2020, 9, 579 8 of 38 
 
Additional studies on the function and interactions among the protein components will further our 
understanding of the regulation of heme synthesis and, thus, the pathophysiology of the anemias 
and porphyrias. 
3. From Heme b to Hemes c, o and a 
All mitochondrial heme species are generated from the heme b produced by FECH (Figure 1). 
Each of the different heme species is necessary for a specific function and is generated by its own 
diverging pathway. While much is known regarding heme synthesis, less is known about heme 
modification and distribution and most available information has been largely elucidated in yeast 
studies. Since the heme b product release by FECH is rate-limiting [100], the interaction between 
FECH and heme chaperone is likely what regulates and distributes heme throughout the cell [12]. 
This protein-mediated shuttling of heme is the probable means of distribution, as “free” heme is 
inherently toxic and can catalyze the formation of harmful reactive oxygen species [12,101]. These 
predictions are in line with a recent report estimating that less than one molecule of exchange-labile 
heme is available in the mitochondrial matrix compartment [92]. 
As noted above, all other species of heme are generated from heme b, including hemes a, heme o 
and heme c. These different species of heme diverge from one another due to various modifications 
of the porphyrin ring. Heme c is the only heme that is covalently bonded to the protein in which it is 
assembled. The two vinyl (C=C) side chains of heme c are covalently attached to the cysteine 
sulfhydryl residues of the apoprotein (Figure 1). Two examples of heme c containing proteins are the 
cytochromes c and c1. Heme o and heme a are formed in a two-step consecutive process by the 
proteins Heme o Synthase (Cox10) and Heme a Synthase (Cox15), respectively. Heme o is modified 
from heme b by the farnesylation of a vinyl group at the C2 position of the porphyrin ring [6,102] and 
heme a has the C8 methyl substituent oxidized to an aldehyde group on top of this [103–106] (Figure 
1). In all cases, heme b must be mobilized from FECH via currently unknown mechanisms to be 
converted into these other heme types.  
In eukaryotes, heme o exists only as long as it takes to convert it to heme a. In some bacteria, 
however, heme o can be used as a prosthetic group in some terminal oxidases, such as cytochrome 
o-containing bo3 oxidase—one of two terminal ubiquinol oxidases in Escherichia coli [107]. The bo3 
oxidase is both structurally and functionally related to cytochrome c oxidase (CcO) of mitochondria 
and bacteria, except that heme o cannot function as a prosthetic group in these other species [108]. 
Heme a is utilized in the active site of Cox1, the central core subunit of CcO, or Complex IV, of the 
electron transport chain (ETC). CcO harbors two heme a molecules—heme a and heme a3—the 
distinction between the two being their coordination geometries within the protein. Heme a is a 6 
coordinate, low spin, cofactor and heme a3 is a 5 coordinate, high spin, cofactor, giving two identical 
molecules with significantly different physical and chemical properties within CcO. This is the only 
known physiological function of heme a [6,108]. In the following sections of this review, we will 
summarize currently available information regarding mitochondrial hemoproteins and highlight 
gaps in our knowledge related to the distribution of different heme species to these proteins.  
3.1. Mitochondrial Heme b Pathways 
Heme b (aka Protoheme IX) is utilized as a cofactor by several mitochondrial 
proteins/complexes (Figure 3). These include mitochondrial matrix-localized flavohemoglobin Yhb1 
(neuroglobin in mammals) [6,109], IMM-anchored ETC enzymes ubiquinol-cytochrome c 
oxidoreductase (complex III, bc1 complex) [110] and succinate dehydrogenase (complex II) 
[6,111,112]. Additionally, yeast mitochondria harbor several fungi-specific hemoproteins such as 
CcO assembly factor Mss51 [113], cytochrome c peroxidase Ccp1 [114] and L-lactate cytochrome c 
oxidoreductase Cyb2 [115]. Remarkably little is known about how heme b is transported to these 
targets. As exemplified by studies on hemylation of complex III, formation of heme b catalytic 
centers is an early post-translational event in the assembly of these molecules [6,116]. Such setting 
likely assures an effective heme-dependent regulatory mechanism, thereby reducing potential 
negative effects of cofactor’s exposure. 
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Figure 3. Mitochondrial heme routes. Mitochondrial enzyme ferrochelatase (FECH) metallates PP IX, 
yielding protoheme that is routed to several suborganellar locales, wherein heme b is sequentially 
modified and/or inserted into the indicated hemoproteins. SDH, succinate dehydrogenase; CcO, 
cytochrome c oxidase; OMM, outer mitochondrial membrane; IMS, intermembrane space; IMM, 
inner mitochondrial membrane. 
3.2. Heme c Pathway 
Unlike the other heme types, heme c needs to be covalently attached to its client proteins – 
cytochrome c (Cyc1) and complex III subunit cytochrome c1 (Cyt1). In each case, hemylation of these 
proteins involves the formation of two stereospecific thioether bonds between two cysteine residues 
of protein’s conserved Cys-X-X-Cys-His motif and two vinyl groups of the protoheme. The histidine 
residue is an axial ligand to heme iron. The covalent attachment of heme to c-type apo-cytochromes 
is critical for their stability and subsequent maturation and has been extensively studied [6,117,118]. 
In yeast, hemylation of apo-Cyc1 and apo-Cyt1 is mediated by either of the two IMS-localized 
cytochrome c heme lyases—CCHL (Cyc3) and CC1HL (Cyt2) [117,119]. In mammals, a single 
enzyme, holocytochrome c synthase (HCCS), is responsible for the covalent heme attachment. All 
mitochondrial CCHL proteins appear to use the following modus operandi: IMM-bound lyase binds 
reduced Fe-PPIX, which is followed by binding of apocytochrome c or c1 and subsequent formation 
of covalent thioether bonds and release of hemylated cytochrome [120]. Although heme binding to 
CCHL proteins is well characterized [120], how reduced heme is transported to CCHL proteins 
across IMM remains to be determined.  
In vitro analyses indicate that c-heme lyases can directly catalyze the formation of a thioether 
bond within the CCHL–ferrous heme-apocytochrome c/c1 complex, wherein apocytochrome 
provides the second histidinyl ligand to this complex with the first axial ligand being supplied by 
invariant histidine residue of CCHL. However, a scenario whereby CCHL proteins merely serve as 
stereospecificity-assuring chaperones allowing for spontaneous thioether bond formation is also 
possible. Likewise, it remains to be determined whether any additional proteins may be facilitating 
this process in vivo. For instance, studies in yeast identified the IMS-residing flavoprotein Cyc2 that 
might function as a heme reductase or redox modulator of heme lyase reactions [121,122]. Because 
Cyc2 is not absolutely required for CCHL function and is not conserved outside fungi, its 
physiological significance remains somewhat unclear. Nevertheless, these findings suggest that 
additional factors may be involved in the maturation of c-type cytochromes in vivo.  
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Once heme is covalently ligated, the resulting holocytochrome c/c1 is released from heme lyase. 
The release is facilitated by several factors including conformational distortion of the heme molecule 
upon its covalent biding to cytochrome c/c1 [120,123] and holocytochrome’s axial ligand-mediated 
dwindling of heme-CCHL adducts [118,120]. Interestingly, the heme lyase’s residues that have been 
implicated in heme coordination also appear to contribute to its release [120]. Upon its hemylation 
the stabilized cytochrome c is further folded into its functional conformation and cytochrome c1 is 
conveyed for further incorporation into maturing bc1 complex. It will be interesting to test whether 
hemylation of cytochromes b and Cyt1 are coordinated molecular events. 
3.3. Heme a Pathway 
Heme a is a modified Fe-PPIX uniquely used by CcO, a key heme-copper enzyme of the ETC 
[6,124]. Two heme a molecules with different coordination geometries—designated a and a3—reside 
in the Cox1 core subunit of CcO and are essential for catalysis and the stability/folding of Cox1 
[6,125]. Hemylation of Cox1 is a sequential post-translational process [6,126,127]. Heme a synthesis 
requires the shuttling of the compound’s precursors—hemes b and o—between heme a biosynthetic 
factors, and the subsequent shuttling of mature heme a to maturing CcO. This process is mediated 
by a number of different assembly factors [128–131], but much remains to be elucidated in terms of 
the molecular mechanisms at work. 
3.3.1. Heme o Synthase 
As discussed earlier, heme o synthase, Cox10, is the protein responsible for converting one of 
the vinyl carbons of the heme b’s macrocycle into a hydrophobic hydroxyfarnesyl tail, yielding heme 
o, the precursor for heme a (Figure 1) [102]. This evolutionarily conserved 46 kDa-enzyme is intrinsic 
to the IMM and it is predicted to contain 8 to 9 transmembrane helices that form a catalytic site on 
the matrix face of the inner membrane. Cox10 assembles in presumably homo-oligomeric complexes 
of approximately 300 kDa [132,133]. Some structure-function insights into Cox10 can be potentially 
gleaned from the recently solved structure of UbiA, a distantly related bacterial prenyl transferase 
[134], but no information exists on how heme b is shuttled to Cox10’s active site. Cox10 
multimerization seems to be dependent upon the presence of newly synthesized Cox1 and its early 
assembly intermediates [131–133]. The oligomerization, but not steady state levels, of Cox10 is 
dependent upon the presence of the yeast-specific Cox10 effector protein Coa2 [132,133]. However, 
the gain-of-function mutation of Cox10, N196K that lies close to matrix side of TMD2 suppresses the 
Coa2 deletion phenotype [132]. Identification of the N196K substitution led to the conclusion that 
Cox10 activation may be linked to a multimeric structure. Because Cox10 is present at approximately 
8-fold lower abundance than the heme a synthase enzyme discussed below, the synthesis of heme o 
is likely the rate-limiting step of heme a production [135]. 
3.3.2. Heme a Synthase 
Heme a synthase, Cox15, catalyzes the conversion of heme o to heme a. Cox15-mediated 
conversion of one ring methyl carbon to a formyl group increases the mid-point potential of heme a 
approximately +180 mV, thereby permitting more efficient catalysis by CcO [136,137]. This enzyme 
is highly conserved from bacteria to humans, allowing for much insight in its function to be 
garnered from model organisms such as Saccharomyces cerervisiae. Cox15 is proposed to have eight 
transmembrane domains (TMDs) and is anchored in the IMM. Of these eight TMDs, models of 
Cox15 predict the protein to contain two domains, each comprised of a 4 helix bundle connected by a 
short (approximately 20 amino acids) unstructured linker region. A very recently solved crystal 
structure of Bacillus subtilis heme a synthase homolog confirms these predictions [138]. Removal of 
the linker region impairs Cox15 function, suggesting its importance in enzyme activity [139]. The 
sequence similarity between the first domain and the second suggest the possibility of a gene 
duplication occurring early in its evolutionary history. Cox15 has been found to form higher-order 
homo-oligomeric protein complexes, on the range of the ~350–450 kDa in size, however the 
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importance of the formation of these complexes on Cox15 enzymatic function remains to be clarified 
[139]. Of note, modeling of the R217W Leigh syndrome (LS)-associated substitution in yeast revealed 
the mutation affects oligomeric properties of Cox15 [139]. In contrast to Cox10, the Cox15 active site 
is predicted to reside on the IMS side of the IMM; no information is available as to how heme o is 
transported across the IM to the Cox15 active site. Another riddle to this is the fact that eukaryotic 
Cox10 and Cox15 do not stably interact [132] and are differentially regulated [135,139]. Unlike 
COX10, COX15 gene expression is regulated by the transcription factor Hap1, which is itself 
regulated by heme concentration [140]. As such, Cox15 protein levels are strictly regulated by heme 
availability [135,139]. It has been suggested by studies of the bacterial Cox15 that the protein 
contains a heme b cofactor [106], however, whether this proposed cofactor is necessary for enzymatic 
function or maintaining protein structure has yet to be determined. There are four invariant 
histidine residues in the protein, two in each of the domains. Mutation of any one of these residues 
in bacterial species was found to ablate heme a [106]. Similarly, in the yeast Cox15, mutations in 
these invariant histidine residues are critical for the enzyme’s function and cannot be substituted 
with other heme-ligating amino acids [139]. The structural study by Niwa et al. [138] on B. subtilis 
heme a synthase indicates that the N-terminal half domain of Cox15 is likely constitutes heme o 
substrate binding site, whereas the C-terminal domain of the enzyme harbors a heme b cofactor 
molecule. This structure also implicated an ultraconserved glutamate residue (Glu-57 in the bacterial 
enzyme) as the catalytic residue [138]. However, the exact mechanistic role of these residues in 
eukaryotic Cox15 remains to be validated. 
In S. cerevisiae, the Cox15-catalyzed conversion of heme o to heme a is known to occur in 
conjunction with the mitochondrial ferredoxin and ferredoxin reductase, yeast adrenodoxin 
homolog 1 (Yah1) and yeast adrenodoxin reductase homologue 1 (Arh1), respectively [103–105,141]. 
The heme b moiety of Cox15 is likely a key cofactor for electrons supplied by this redox couple. Yah1 
and Arh1 are mitochondrial [2Fe-2S] proteins that are important for the maturation of Fe/S proteins 
[142,143]. Yah1 receives its electrons from Arh1, which utilizes NADH as its electron source. These 
two proteins supply Cox15 with electrons and thus are critical for the formation of heme a [103,141]. 
Of note, in Schizosaccharomyces pombe Yah1 and Arh1 exist as portions of a tandem fusion protein 
[144]. The yeast Yah1 functions as an electron donor for both heme a and iron-sulfur cluster 
biosynthetic machineries, whereas mammalian mitochondria are equipped with two isoforms of 
ferredoxin—FDX1 and FDX2—where FDX1 functions specifically in steroidogenesis and FDX2 is 
specific for heme a and iron-sulfur cluster biogenesis [145]. 
3.3.3. Other Proteins Related to Heme a Biogenesis 
Additional factors have been implicated in maturation and/or transport of heme a to its final 
destination. This group of proteins includes CcO assembly factors Pet117, Shy1/SURF1 and the 
yeast-specific protein Coa2.  
Pet117 was identified as a conserved 107-amino acid-long CcO assembly factor by McEwen et al. 
[146]. Since its discovery, little work has been done to characterize the protein. Deletion of the 
PET117 gene was shown to have a reduction in heme a levels [147], indicating that Pet117 may 
function in heme a biosynthesis in some manner. We recently showed that Pet117 is the 
mitochondrial protein localized to the matrix side of the IMM [148]. More importantly, we 
discovered that Pet117 stably interacts with Cox15; this interaction is independent of catalytic 
function of Cox15, but deletion of the 20-amino acid unstructured linker region of Cox15 abolishes 
the interaction. While Pet117 does not appear to be a heme-binding protein per se, its deletion results 
in a loss of Cox15 oligomerization, indicating that Pet117 promotes stabilization of Cox15 oligomers, 
thus facilitating heme a biosynthesis. Based on the observation that the Pet117-Cox15 interaction is 
ablated in mitochondria lacking Cox1 transcriptional activator Mss51 [148], it is tempting to 
speculate that Pet117 may be coupling Cox15 oligomers to maturing Cox1 assembly intermediate.  
Shy1/SURF1 is a conserved IM-anchored CcO assembly factor whose exact function has yet to 
be clarified. In both yeast and mammals, newly synthesized Cox1 progresses through a series of 
intermediates containing different assembly factors. Formation of the heme a3:CuB bimetallic center 
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appears to occur in an intermediate containing Shy1 [126,131][149]. It remains unclear, which Cox1 
assembly intermediate triggers Cox10 and Cox15 activation and oligomerization [133]. Recent 
reports indicate that Shy1 substoichiometrically associates with Cox15, so Shy1 is likely to play a 
certain role in CcO hemylation [149]. Studies with recombinant Pseudomonas denitrificans SURF1 
isoforms shown the protein can stoichiometrically bind heme a, leading to the conclusion that this 
protein can act as a heme chaperone in Cox1 hemylation [150,151]. However, subsequent analyses of 
Shy1/SURF1 in eukaryotes have challenged this postulate. Shy1 is partially dispensable as null 
mutants retain a significant percent of CcO activity [152]. In the human Shy1 homologue, SURF1, the 
same is true for several cases of the truncating SURF1 mutation [153]. In yeast, SHY1 mutants only 
produce 10–15% of the fully functional CcO complex, similar to Leigh Syndrome (LS) patients who 
exhibit 10–30% of normal CcO. Moreover, mutation of conserved candidate heme-ligating residues 
had little to no effect on the protein’s function indicating that Shy1 is unlikely to be a dedicated heme 
chaperone [152]. Shy1/SURF1 may thus be simply facilitating CcO hemylation by stabilizing the 
maturing Cox1 subunit, but further analyses are warranted to validate this model. 
Coa2 is an assembly factor for CcO in yeast, originally identified as a high-copy genetic 
suppressor of the shy1 mutation [154]. This small (~11 kDa), matrix-localized protein functions 
downstream of insertion of newly synthesized Cox1 into the IM and it has been shown to physically 
interact with Shy1 [154]. The newly synthesized Cox1 is rapidly degraded in the absence of Coa2, 
presumably due to impaired hemylation and misfolding of this CcO subunit [132,154,155]. Just like 
Shy1/SURF1, Coa2 does not appear to be a bona fide heme chaperone, but its deletion affects 
oligomerization of both Cox10 [132,133] and Cox15 [133]. Interestingly, our data suggest that unlike 
Cox10, Cox15 still oligomerizes in coa2∆ cells, but that the complex is more labile and collapses 
under blue native electrophoresis conditions (our unpublished data). This indicates that Coa2 is 
likely not required for Cox15 oligomerization but plays more of a stabilizing role for Cox15 
oligomers, similar to the Pet117 protein. As mentioned previously, the respiratory defect of 
coa2cells is specifically suppressed by the dominant gain-of-function N196K mutation in Cox10 
[132] or—to much lesser extent—by the enhanced Cox1 synthesis [133]. Consistent with Coa2’s role 
in HOS oligomerization, both suppression mechanisms are associated with the abundance of Cox10 
oligomer. These observations led to a conclusion that Coa2 may be important for coupling Cox1 
synthesis to Cox15 oligomerization and/or activity [133]. An outstanding question remains if such 
principles can be applied to mammalian heme a transport, as it is currently unclear whether a 
human homolog of Coa2 exists. 
3.4. Heme c and Heme a Pathway-Related Diseases 
Several human diseases stem from defects in heme c and heme a pathways. The hereditary 
dominant microphthalmia with linear skin defects (MLS) syndrome-associated mutations in HCCS 
have been linked to both defective heme binding and cytochrome c release, highlighting the 
importance of these processes to human physiology [156,157]. These findings also strongly suggest 
that heme binding to CCHL proteins is a rate-limiting step in cytochrome c maturation. 
Mutations in conserved residues of Cox10, Cox15 and SURF1 manifest in tubulopathy and 
leukodystrophy [158], sensorineural deafness [159], fatal infantile hypertrophic cardiomyopathy 
[159–161], Charcot-Marie-Tooth disease type 1A [162] and neurologic LS [153,159,163–170]. Of note, 
pathologic mutations in SURF1 account for the majority of cases of LS associated with CcO 
deficiency [171]. 
The yeast Pet117 has a human orthologue that is approximately 81 amino acids in length and 
that has not been thoroughly studied. One study proposed that human PET117 might be involved in 
copper insertion to CcO [172]. However, more recent reports have challenged that idea. In addition 
to our study in yeast, a premature stop codon patient mutation in PET117 has been identified [173]. 
This mutation results in a LS-like condition from complex IV deficiency—reduction in steady state 
levels of complex IV as well as the core subunits, Cox1–3 and reduction in complex IV activity levels. 
Treatment of patient fibroblasts with exogenous copper was unable to rescue the complex IV 
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deficiency, indicating that PET117 likely does not function as a copper chaperone [173]. The role of 
PET117 in heme a biosynthesis in humans has yet to be clarified. 
4. Extra-Mitochondrial Heme Trafficking 
Cellular heme is either derived endogenously from de novo synthesis or exogenously from 
heme uptake (Figure 4) [2,3,174]. Once synthesized by FECH or transported into the cell, heme must 
be mobilized and delivered to heme-dependent proteins residing in virtually every subcellular 
compartment. As with other transition metals, e.g., copper or iron, it is generally assumed that heme 
distribution is mediated by the coordinated action of heme transporters, chaperones and carrier 
proteins [2,3]. However, unlike other transition metals, heme is also a hydrophobic lipid-like 
molecule [3]. This raises the possibility that heme could be trafficked like other mitochondrial 
derived lipids via vesicles or through contact sites between organelles. In this section, we highlight 
our current understanding of the journey heme takes from its site of synthesis or uptake to locations 
throughout the cell. 
 
Figure 4. Schematic representation of heme trafficking within a eukaryotic cell. Heme synthesis is 
completed within the matrix of the mitochondria; from here heme (red polygons) is mobilized 
throughout the cell to the cytosol, IMS, peroxisome, lysosome, endoplasmic reticulum (ER), Golgi, 
nucleus and extracellular space. Known heme buffering factors and transporters are highlighted, any 
unknown pathways are marked with question marks. 
4.1. Exit of Mitochondrial Heme 
How is heme trafficked out of the mitochondria? One possibility is that it is exported via 
dedicated heme transporters (Figure 4). The only mitochondrial heme transport protein identified to 
date is Feline leukemia virus subgroup C receptor-related protein 1b (FLVRC1b), a member of the 
major facilitator superfamily (MFS) of secondary active transporters [175]. FLVCR1b is a six-TMD 
protein that is derived from an alternative transcriptional start site located within the first intron of 
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Flvcr1 [175], which otherwise encodes FLVCR1a, a twelve TMD plasma membrane heme exporter 
[14,176]. The primary evidence of the role of Flvcr1b in mitochondrial heme export stems from 
over-expression and depletion studies; silencing of Flvcr1b transcript using siRNA results in 
mitochondrial heme accumulation and termination of erythroid differentiation while 
overexpression results in increased cytosolic heme [175]. While the genetic evidence for the role of 
Flvcr1b in heme export is quite strong, there are a number of unresolved questions. For instance, 
there is still no direct biophysical evidence that Flvcr1b can transport heme or mechanistic 
understanding of heme translocation. Interestingly and quite importantly, a segment of Flvcr1a 
found to be important for heme binding and transport, e.g., residues 132–201 and in particular 
His-145, Tyr-153 and His-198, are missing in Flvcr1b [177]. Additionally, it is not known whether 
Flvcr1b is located on the inner or outer mitochondrial membranes, which will have implications for 
where it acquires and transports heme, i.e., matrix to IMS vs. IMS to cytosol. In the context of the 
heme metabolon, it is tempting to speculate that Flvcr1b could interact with FECH or other 
components of the heme biosynthetic machinery and accept heme for transport immediately upon 
its synthesis. However, data from affinity purification studies of FECH do not support this 
interaction [82]. 
Affinity purification data do support interactions between FECH, PGRMC1 and PGRMC2 [83]. 
Both PGRMC1 and PGRMC2 have been proposed to be heme chaperones [90,178,179]. As mentioned 
earlier PGRMC1 and PGRMC2 are both proteins that bind heme with moderate affinity and either 
stimulate hemoproteins including cytochrome P450s [87–89] or alter labile heme levels in different 
cellular compartments [90]. Interestingly PGRMC1 has been localized to multiple cellular locations 
including the ER [180], mitochondria [83], nucleus [181] and cellular membrane [182], while 
PGRMC2 is an ER protein [90]. Multiple studies have found that PGRMC1 and PGRMC2 interact 
[90] and recent studies using adipose-tissue specific knock out of PGRMC2 or both PGRMC2 and 
PGRMC1 result in nuclear heme homeostasis disruption and metabolic dysfunction [3]. Thus, 
PGRMC1 and PGRMC2 have been proposed to function as a conduit for heme transport from FECH 
in the mitochondrial matrix to the ER and nucleus [90]. Further studies of these proteins will shed 
light of the mechanisms by which these proteins function in cellular heme trafficking. 
Instead of heme export from the mitochondria via a single transport protein, there are likely 
multiple routes of heme export. Indeed, S. cerevisiae does not encode Flvcr1 homologs and has a 
single PGRMC1 and PGRMC2 protein (Dap1), implying the presence of alternative heme transport 
mechanisms (Figure 4). In addition to other yet to be determined heme transporters, alternative 
pathways for mobilizing mitochondrial heme involves its passage through membrane contact points 
or vesicular trafficking to other organelles [3]. With respect to the former, there may be direct heme 
transfer between the mitochondrial and ER networks via mitochondria-associated membranes 
(MAMs). MAMs form a contiguous interface between the mitochondrial outer-membrane and the 
endoplasmic reticulum (ER) via the ER-mitochondria encounter structure (ERMES). While ERMES 
has previously been implicated in facilitating the exchange of lipids between the ER and 
mitochondria, it may also serve as a route for heme transfer as well [183]. While direct evidence for 
the role of MAMs and ERMES in facilitating heme exchange is lacking, it is worth noting that a 
number of heme homeostatic factors, including CPOX, FECH, heme-binding protein 1 (HBP 1), 
heme oxygenase-2 (HO-2) and PGRMC1 have been found to associate with MAMs [184,185]. Since 
the ER network extends between the nucleus, Golgi and secretory pathway, once heme exchanges 
into the ER, it can bind to any number of hemoproteins present in these locations, as well as proteins 
that are eventually secreted or are directed to the lysosome, peroxisome, or plasma membrane. 
However, the mechanisms underlying heme distribution in the ER or Golgi are currently unknown. 
Another potential mechanism for the export of mitochondrial heme is via mitochondrial-derived 
vesicles (MDVs) [186]. MDV’s have been found to traffic material to peroxisomes and lysosomes and 
it is possible that heme may also be packaged in these vesicles as cargo.  
4.2. Import of Exogenous Heme 
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Heme can be acquired from exogenous sources in addition to de novo synthesis. As with 
mitochondrial heme export, heme import could be mediated by a number of different mechanisms, 
including transporters, hemoprotein receptors, endocytic pathways or lipid carriers (Figure 4). The 
first bona fide eukaryotic heme transporters, HRG-1 and HRG-4, were identified using molecular 
genetic approaches in Caenorhabditis elegans. As a heme auxotroph, all heme in C. elegans is derived 
from nutritional sources and is mobilized from the intestines to tissue throughout the animal [187]. 
Heme responsive genes HRG1 and HRG4 were first identified from a transcriptomic screen as genes 
that are up-regulated during growth on low heme and were later determined to be involved in 
intestinal heme uptake in worms [188]. HRG-4, which lacks mammalian homologs, localizes to the 
plasma membrane, while HRG-1, which is conserved from arthropods to vertebrates, including 
mammals (20% identity between human and C. elegans HRG1), is present in endosomes and 
transports exogenously-derived heme into the cytosol. 
Human HRG1 is predicted to have four TMD-spanning helices [188,189] and functions 
cooperatively with a V-type H+-ATPase. Indeed, acidification of endosomes is necessary to protonate 
heme coordinating residues of hemoproteins to facilitate the release of heme, solubilize unbound 
“free” heme and couple heme export out of endosomes to a proton gradient [189]. A number of lines 
of evidence have implicated HRG1 as a heme transporter, including (i) HRG-1-mediated import of 
heme into Xenopus oocytes; (ii) HRG-1-mediated transport of zinc mesoporphyrin (ZnMP) into the 
C. elegans intestine and ectopically expressing murine cells; and (iii) HRG-1 heme transport activity 
using yeast reporter assays. Furthermore, a number of highly conserved heme-binding His and Tyr 
residues are critical for HRG1 activity [190]. Functionally, HRG-1 is critical for mobilization of heme 
from the phagolysosome of macrophages during erythrophagocytosis [191] and heme uptake and 
utilization in the C. elegans intestine [188]. 
An additional putative cell surface heme transporter is FLVCR2 [192]. Indeed, FLVCR2 binds to 
hemin-agarose, FLVCR2 overexpression in Chinese hamster ovary (CHO) cells and Xenopus laevis 
oocytes leads to accumulation of exogenous heme and enhanced sensitivity to heme toxicity and 
FLVCR2 depletion by siRNA leads to reduced accumulation of the fluorescent heme analog, zinc 
mesoporphyrin. On the other hand, unlike HRG-1 and HRG-4, when FLVCR2 is expressed in a yeast 
system, it cannot transport heme to rescue heme-deficient strains [190]. Furthermore, while there is 
no clear physiological role for FLVCR2 in regulating heme homeostasis in vivo, it is interesting to 
note that Fowler syndrome, a vascular disorder of the brain that is caused by mutations in FLVCR2, 
is associated with defects in the activity of heme-containing respiratory complexes [192].  
Another mechanism of heme import is via the uptake of hemoproteins. Haptoglobin and 
hemopexin, a pair of serum heme-scavenging proteins, bind to hemoglobin and heme, respectively 
released during hemolysis or cellular injury. Haptoglobin, which is secreted from hepatocytes, binds 
plasma hemoglobin with high affinity, KD ≈ 10−12M [193] and this complex is endocytosed by 
macrophages via the receptor CD163 [194]. The heme from hemoglobin is subsequently released 
during endosomal acidification and imported into the cytoplasm and recycled by macrophages 
[195]. Hemopexin, which is primarily produced by the liver, binds “free” heme in the plasma with 
high affinity, KD ≈ 10−13M [196] and this complex is endocytosed via the LRP1/CD91 receptor [196–
198]. While LRP1 clearly plays a role in heme catabolism in the liver, its presence and role in cells 
other than hepatocytes is unclear and suggests it may function in heme uptake for utilization or as a 
source of iron [198]. 
In addition to heme transporters and receptor-mediated endocytosis of hemoproteins, heme 
uptake may also be mediated by the endocytosis of heme-loaded microparticles derived from red 
blood cells [199–202]. Although typically associated with red blood cell storage lesions or sickle-cell 
disease, circulating erythrocytes can release heme-laden microparticles that are highly 
inflammatory. These particles are endocytosed by endothelial cells in a Rab5-dependent manner 
[203] and constitute an additional mechanism of heme uptake by cells. 
Another mechanism for the uptake of extracellular heme in mammals involves its sequestration 
by lipoprotein particles that can subsequently be endocytosed [101]. Free heme has the capacity to 
partition into low-density lipoproteins (LDLs) and high-density lipoproteins (HDLs) despite the 
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presence of heme-scavenging proteins haptoglobin, hemopexin and albumin [101]. Once 
internalized, lipoproteins can release heme from acidic endosomal compartments. Altogether, 
multiple mechanisms account for the cellular import of exogenous heme for utilization or 
catabolism. Pathways for the endocytosis of exogenous heme have been identified in yeast as well, 
including budding and fission yeast, S. cerevisiase and S. pombe, respectively. In S. cerevisiase, 
FECH-depleted hem15∆ cells can be rescued by heme in fermentable media but not in 
non-fermentable media while cells are respiring [204,205]. The mechanism by which yeast cells 
import exogenous heme and the basis for why mitochondrial heme import is inefficient is not 
completely clear. A recent study identified gain-of-function mutant variants of the plasma 
membrane protein Nce102 as a genetic suppressor of respiratory defects in heme-supplemented 
hem15 mutants [83]. While the exact suppression mechanism remains elusive, the eisosome 
complex-related Nce102 [206] is likely to facilitate the uptake of exogenous heme via the endocytic 
pathway, wherein direct short-lived interactions between endosome and mitochondria mediate 
heme transfer between these subcellular compartments. In S. pombe, exogenous heme is endocytosed 
and trafficked to the vacuole for storage in a manner dependent on internalization by Shu1, a cell 
surface receptor and vacuolar transport by the ESCRT pathway [207–210]. 
4.3. Exogenous vs. Endogenous Heme 
A long-standing dogma in heme cell biology field is that the cellular heme quota is solely 
dictated by de novo synthesis and degradation; any imported exogenous heme is thought to be 
degraded by heme oxygenases (HO) and the released iron is siphoned for de novo heme synthesis, 
stored, or utilized for any number of other iron-dependent processes. However, two major 
challenges to this paradigm are that: (i) heme supplementation rescues a number of cell and animal 
systems that are defective in heme synthesis, suggesting exogenous heme may in fact be recycled 
and reused independently of heme degradation [187,211,212]; and (ii) heme exporters [13,14] and 
inter-cellular heme chaperones [213] have been identified, which strongly suggests that heme can be 
shared between cells. Taken together, these new findings have prompted us to re-think the 
traditional paradigm that all heme for use in metabolism is derived from de novo synthesis in the 
mitochondria. However, the relative contributions of endogenously synthesized heme and 
exogenously supplied heme to cellular heme pools need to be determined. Further, there is little 
understanding of how imported heme is trafficked for degradation by HO in the ER or how cells 
bifurcate the flow of exogenous heme between HO and other heme-dependent processes. 
A wealth of data indicates exogenous heme may be utilized in toto independently of its 
degradation. In the unicellular model eukaryote, yeast S. cerevisiae, hem1∆ cells, lacking the first 
enzyme in the heme synthesis pathway, ALA synthase, can be rescued to some extent by heme 
supplementation [204,205]. Further, in humans, patients suffering from certain porphyrias, a class of 
disorders characterized by heme synthesis defects, can be treated with intravenous heme and 
heme-albumin, which rescues heme-dependent enzyme activities in various tissues [214]. However, 
it is unclear how imported heme is distributed for use in metabolism in a manner that bypasses HO 
or what the mechanisms of heme uptake are for the mitochondria and other subcellular 
compartments. Interestingly, using horseradish peroxidase activity-based heme reporters targeted 
to different subcellular compartments in HEK293 cells, it was determined that exogenous and 
endogenous heme is trafficked differently to various subcellular compartments [174]. However, the 
mechanisms underlying the hierarchical distribution of exogenous and endogenous heme to various 
cellular locales are unknown.  
What are the mechanisms underlying the mobilization of heme out of the cell and what is the 
rationale for such a process? FLVCR1a is a 12 TMD plasma membrane heme export protein of the 
major facilitator superfamily of transporters. FLVCR1 was first discovered as a receptor for feline 
leukemia virus (FeLV) and its involvement in heme homeostasis was established based upon the 
development of aplastic anemia due to a loss of erythroid progenitors upon FeLV infection. It was 
subsequently determined that FLVCR1a is a cytoplasmic heme exporter that protects developing 
erythroid cells from heme toxicity and susceptibility to anemia [14,176]. As mentioned earlier, it was 
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later determined that an alternative transcriptional start-site located within the first intron of 
FLVCR1a results in a shorter transcript that produces a truncated 6 TMD isoform, FLVCR1b, which 
transports heme out of the mitochondria [175]. Further, another FeLV receptor, the homologous cell 
surface protein, FLVCR2, was implicated as a heme importer [192]. 
FLVCR1a is thought to primarily protect cells from heme toxicity. For instance, it is thought that 
FLVCR1a exports heme from macrophages during erythrophagocytosis of senescent red blood cells. 
In fact, FLVCR1a interacts with hemopexin, an extracellular heme scavenger and exports heme > 
100-fold more efficiently in the presence of hemopexin [215]. Further, FLVCR1a protects developing 
red blood cells from heme toxicity by acting as a safety valve to export potentially cytotoxic heme. In 
addition to its role in protecting cells from heme toxicity, there may also be inter-cellular signaling 
functions for heme. For instance, as a pro-inflammatory signaling molecule, erythrocyte-derived 
heme can differentiate and activate macrophages for clearance of red blood cells [15].  
In addition to FLVCR1a, another mechanism for cellular heme export involves MRP-5, an ABC 
transporter (Figure 4) [216]. Loss of MRP-5 leads to embryonic lethality in C. elegans that can be 
rescued by addition of exogenous heme. Further, Mrp5 deficient mice have reduced heme levels in 
the secretory pathway of embryonic fibroblasts. However, Mrp5−/− mice do not show overt 
heme-related phenotypes, possibly due to compensation by other ABC-transporters. Taken together, 
like FLVCR1a, MRP5 provides yet another conduit for heme export from the cell; though its precise 
physiological function is unclear. Yet another protein shown to be involved in heme export is 
ABCG2, also known as the breast cancer resistance protein (BRCP). ABCG2 is an ATP-binding 
cassette transporter which has been shown to transport heme, hemin and porphyrin in addition to a 
variety of medications [217–221]. ABCG2 is expressed by a variety of normal tissues including 
placenta, brain, small intestines, ovary, liver and hematopoetic stem cells, as well as in a number of 
cancer cells [222]. Recent studies have shown that ABCG2 exports heme to serum albumin and that it 
functions in cellular protection [217]. While these export proteins suggest a protective function by 
which heme or porphyrin that is overexpressed or accumulated is exported for catabolism, such a 
process seems wasteful and potentially dangerous to the organism. 
Another route for heme mobilization from cells is through secreted hemoproteins. In C. elegans, 
HRG-3, a 8 kDa intercellular heme chaperone protein, binds and delivers maternal heme to 
developing oocytes [213]. These results suggest that heme can be transferred between tissues and 
cell types as a nutritional heme source. However, the degree to which this happens in higher animals 
during development is unclear. Altogether, the identification of heme export pathways and heme 
rescue of phenotypes associated with defects in heme synthesis suggests heme can be utilized for 
metabolism independently of heme catabolism pathways. 
4.4. Heme Trafficking Factors 
The factors that regulate heme bioavailability and distribution are poorly understood. 
Historically, biochemically driven approaches toward probing heme homeostatic mechanisms and 
defining the heme proteome have been instrumental. For instance, cellular heme-binding proteins 
(HBPs) have been identified on the basis of their interaction with heme-agarose or blue-sepharose. 
These HBPs include 22 kDa HBP, 23 kDa HBP, SOUL, glutathione-S-transferase, fatty acid-binding 
protein (FABP) and glyceraldehyde phosphate dehydrogenase (GAPDH) [2,3,223]. However, with 
the exception of GAPDH, it is not known what role these HBPs play in regulating heme homeostasis. 
GAPDH was not only found to regulate heme insertion into nitric oxide synthase in a 
NO-dependent manner [224], but also found to buffer cytosolic heme and regulate its availability to 
a nuclear heme regulated transcription factor [91,92]. 
5. Multi-Model Comparison of Eukaryotic Heme Homeostasis 
All heme-requiring organisms occupy a position on the continuum between relying exclusively 
on de novo heme synthesis and heme uptake. Most eukaryotes, including mammalian cells, are in 
the middle of this continuum and can both import and synthesize heme efficiently [174]. As 
mentioned previously, organisms like C. elegans, rely exclusively on heme uptake from nutritional 
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sources and cannot make their own heme due to the lack of a functioning heme biosynthetic 
pathway [187]. As an interesting aside, these nematodes retained a pseudo FECH protein, encoded 
by the gene fechl-1 (accession code: K07G5.6), with 23% identity to mammalian FECH. While this 
protein is expressed, it lacks canonical FECH activity [187,225,226]. Several other organisms 
including the cattle tick Rhipicephalus (Boophilus) microplus [227] and the Atlantic salmon louse 
Lepeophtheirus salmonis [228] are heme auxotrophs as well. S. cerevisiae, on the other hand, is not 
efficient at importing heme and is almost exclusively reliant on heme synthesis [211]. Since much of 
our current understanding of eukaryotic heme homeostasis comes from work in Baker’s yeast, 
mammalian cell lines and C. elegans, we have a window into common and divergent themes in heme 
homeostatic pathways of organisms that occupy different positions on the continuum of heme 
acquisition between synthesis and uptake (Table 1). 
First, if an organism can make heme, eukaryotic heme synthesis is highly conserved and all 
eight heme biosynthetic enzymes share a high degree of homology across eukaryotic species. 
Second, all eukaryotes have the capacity to export heme, but with divergent mechanisms. For 
instance, Baker’s yeast expresses Pug1, a porphyrin-heme exchanger that imports PP IX while 
exporting heme [211]. On the other hand, in the model metazoan, C. elegans, intestinal heme is 
shared via a secreted hemoprotein, HRG3, that delivers heme to other tissues. In vertebrates, the 
heme transporter, FLVCR1a, is used to export heme into the extracellular space. On the basis for its 
conservation between worm and man, one mechanism that may be common for heme export is 
secretion via the secretory pathway, as proposed for MRP5-mediated heme export. Third, the import 
of heme is generally poorly defined across eukaryotes. While cell surface heme importers are known 
for C. elegans, e.g., HRG4, this factor is not well conserved in lower or higher eukaryotes. For 
instance, it is still not known what the high affinity heme importer is for mammalian cells or even if 
there is one. On the other hand, low affinity heme uptake factors like FLVCR2 and the folate 
transporter, HCP-1, have previously been identified in mammalian cells [3]. Fourth, the factors that 
mediate intracellular heme trafficking are largely unknown in any eukaryote. Two exceptions are 
GAPDH [91,92,224] and PGRMC1/2 [89,90], which are the only factors found to play roles in 
intracellular heme trafficking in both yeast and human cells lines, albeit their molecular mechanisms 
are not known. Overall, while heme synthesis is highly conserved across all of eukaryotic life, the 
transport and trafficking of heme is not and likely reflects the unique ecological niches that life 
adapted to in order to acquire heme and control its bioavailability. 
6. New Methods to Probe Heme Trafficking 
Total heme in the cell can be considered to be a sum of exchange-inert and exchange-labile 
pools [2]. Exchange-inert heme corresponds to heme buried in the active sites of high affinity 
hemoproteins, e.g., globins and cytochromes and is not readily exchangeable. On the other hand, 
exchange-labile heme can readily exchange between proteins and defines the bioavailable pool 
relevant to heme trafficking and signaling. Until recently, there were no methods to monitor 
bioavailable heme in intact living cells and most measurements simply reported “total” heme or the 
most highly absorbing and/or abundant hemoproteins (Table 2). As a highly colored pigment, 
historically, most measurements of heme from cell and tissue extracts involve the use of UV-visible 
absorbance spectroscopy. Indeed, heme exhibits Soret band extinction coefficients between ~30,000 
cm−1 M−1 and ~200,000 cm−1 M−1 in the 390–420 nm spectral region, depending on oxidation state and 
the nature of coordinating protein ligands [136]. In samples with low turbidity, including body 
fluids like plasma, heme can readily be quantified from UV-vis spectroscopy. In addition, since the 
spectral characteristics of heme are sensitive to the identity of coordinating ligands and heme iron 
oxidation state, spectral deconvolution can resolve free non-proteinaceous heme from hemoglobin 
(Hb) [229]. Moreover, oxyHb and metHb can be readily differentiated as well [229]. However, due to 
light scattering in many biological matrices, including cells and tissues, heme is often extracted using 
strong acid, which serves to dissociate heme from proteinaceous ligands and organic solvents like 
acetone or butanol, which separates heme from the aqueous phase [230]. Extracted heme can be 
chromatographed by high performance liquid chromatography (HPLC) using a reverse-phase C18 
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column coupled to an in-line UV-vis detector for quantification [231,232]. This method allows for 
differentiating heme b from other heme types, including heme o or heme a [233]. Alternatively, 
extracted heme or heme from soluble lysates or isolated hemoproteins may be quantified using the 
pyridine hemochromagen assay, which is based upon the distinct spectral features of the 
bis-pyridine ferrous heme complex [234–237]. The development of commercial instrumentation to 
measure absorbing species in turbid samples, including in cells and tissues, has greatly facilitated 
the measurement of heme in biological matrices. The Olis CLARiTY UV-vis spectrophotometer 
employs a quartz cuvette within an integrating cavity absorption meter (ICAM) [237]. The quartz 
cuvette contains a reflective coating that effectively increases the path length, making the instrument 
much more sensitive to absorption of light in turbid samples [237,238]. Finally, the measurement of 
porphyrin fluorescence is a very sensitive technique for the quantification of heme, with a limit of 
detection of 10−9M [232,233]. While heme itself is non-fluorescent, de-metallation of the heme iron in 
boiling oxalic acid results in the formation of fluorescent PP IX free base (λex = 400 nm; λem = 662 nm) 
[232,233].  
Table 2. Approaches to measure total and labile heme in cells and tissues. References are in the text. 
Approaches Methods Advantages Disadvantages 
In Situ Label Free 
Imaging 
Transient Absorption 
Microscopy 
Resonance Raman Imaging 
2 Photon Photothermal Lens 
Microscopy 
Subcellular resolution (< 1 
μm) 
Non-invasive 
Can probe heme dynamics 
in living cells 
Signals dominated by most 
abundant and/or highly 
absorbing species 
Low-throughput 
Requires specialized 
equipment/expertise 
In Situ Imaging of Labile 
Heme using Fluorescent 
Heme Sensors 
HS1 
CISDY-9 
CHY 
Subcellular resolution (< 1 
μm) 
Direct probe of labile 
“bioavailable” heme 
Can probe heme dynamics 
in living cells 
High-throughput 
May perturb heme 
homeostasis 
Possible selection bias 
depending on the nature of the 
sensor 
Extended time resolved 
studies precluded by 
photobleaching 
Assays for Endogenous 
Markers of Heme 
Bioavailability 
Horseradish Peroxidase 
Tryptophan 2,3 Dioxygenase 
(TDO) 
Indoleamine-2,3-Dioxygenase 
(IDO) 
Cytochrome P450 
Catalase 
Transcription Factors 
Measurement of heme 
accessible to endogenous 
hemoproteins 
No genetic perturbations 
Disruption of cells and tissues 
Time consuming 
Difficult to get fast time 
resolution 
 
Assays for Total 
Heme 
HPLC 
Resolve different heme 
types 
Time consuming 
Disruption of cells and tissues 
Low-throughput 
Porphyrin Fluorescence 
nM sensitivity 
High-throughput 
Disruption of cells and tissues 
UV/vis CLARiTY Sensitive measurements in Signals dominated by most 
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Absorbance 
Spectroscopy 
turbid samples 
Possible to measure heme 
and hemoproteins in 
intact cells 
abundant and/or highly 
absorbing species 
Low-throughput 
Requires specialized 
equipment 
Pyridine Hemochromagen 
Broadly accessible 
Inexpensive 
Disruption of cells and tissues 
Although the aforementioned methods serve as powerful tools for measuring heme, they suffer 
from a number of drawbacks. First, these methods often rely on cell and tissue disruption and 
homogenization, which is time consuming, technically demanding and may result in the loss of 
heme from the samples. Second, they do not provide information on heme distribution and 
localization, unless great care is taken to isolate organelles and subcompartments. Third, these 
methods do not resolve heterogeneity within populations of cells or the spatio-temporal dynamics of 
heme. Fourth, these methods fail to resolve the differences between total and bioavailable heme, the 
latter of which defines the pool of heme accessible for all heme-dependent functions. 
Traditional methods to probe heme bioavailability involve assaying the activities of various 
heme-dependent enzymes and transcription factors in cell or tissue extracts, including cytochrome 
P450 enzymes (ER) [239,240], catalase (peroxisomes or mitochondria) [92,241], tryptophan 2,3 
dioxygenase (cytosol) [242], indoleamine-2,3-dioxygenase (cytosol) [243], various nuclear 
transcription factors, e.g., Hap1 (in yeast), Bach1, p53 and Reverb-α/β [2,3,92,241] and peroxidases 
that can be genetically encoded and targeted to different subcellular compartments [174,244] (Table 
2). While these methods have shed considerable insight into heme homeostatic mechanisms, they 
suffer from a number of drawbacks that arise from harsh lysis conditions and time-intensive enzyme 
assays. Therefore, these enzymatic assays may artifactually alter bioavailable heme pools due to the 
repartitioning of heme upon cell lysis and are unsuitable for probing the spatial and temporal 
dynamics of cellular heme due to the challenges associated with rapidly isolating organelles. 
More recently, the development of genetically encoded fluorescent heme sensors has 
revolutionized the ability to image and probe labile heme relevant to its trafficking and signaling in 
intact living cells and subcellular compartments, circumventing the need for cell disruption and 
time-intensive enzyme assays. Independently and virtually contemporaneously, three labs reported 
the development of genetically encoded ratiometric fluorescent heme sensors. Song et al., [245] 
reported the first FRET sensor for cellular heme imaging. The sensor, CISDY, consists of a heme 
sensing moiety containing NEAT domains of a pair of heme transfer chaperones, IsdX1 and IsdC, 
tethered by a linker and flanked by enhanced cyan and yellow fluorescent proteins (ECFP and 
EYFP) at the N and C terminus, respectively. Heme binding induces the dimerization of IsdX1 and 
IsdC, resulting in an increase in the FRET efficiency between ECFP and EYFP. Expression of CISDY 
across various human cell lines and in locations spanning the cytosol, nucleus, mitochondria and ER, 
revealed labile heme to be ~20 nM in all these compartments.  
Following this development, Hanna et al., [92] reported the FRET-based heme sensor 1 (HS1), a 
fusion of cytochrome b562 (Cyt b562), enhanced green fluorescent protein (EGFP) and a red fluorescent 
protein, Katushka 2 (mKATE2). Heme binding to Cyt b562, a His/Met heme-binding protein from E. 
coli [246], results in > 90% quenching of EGFP fluorescence via FRET. mKATE2, on the other hand, is 
a poor FRET donor to heme [92] and its fluorescence is relatively insensitive to heme binding to the 
Cyt b562 module. Thus, the ratio of heme-sensitive EGFP fluorescence to heme-insensitive mKATE2 
fluorescence provides a readout of cellular heme. The application of HS1 has uncovered 
fundamental insight into heme trafficking, dynamics and signaling. For instance, the HS1 variant, 
HS1-M7A, was used to screen the yeast gene deletion collection to identify genes that regulate heme 
bioavailability. One factor that was identified to regulate heme bioavailability and trafficking to a 
nuclear heme-regulated transcription factor was the glycolytic enzyme, GAPDH [241]. Further, 
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using HS1-M7A, it was found that subcellular heme pools are highly dynamic and can be mobilized 
by signaling molecules like nitric oxide (NO) [92] and heavy metal stress [241]. 
Even more recently, Abshire et al. [247] reported a FRET-type sensor consisting of the 
Plasmodium falciparum histidine-rich heme-binding protein 2 (PfHRP2) flanked by ECFP and EYFP as 
FRET donor and acceptor proteins, respectively. Heme binding to PfHRP2 results in a lowering of 
the fluorescence lifetime of ECFP due to energy transfer to the heme moiety and therefore a decrease 
in FRET between ECFP and EYFP. While the heme sensor domain non-cooperatively binds ~15–18 
heme molecules/monomer with an apparent dissociation constant of ~0.3 μM, a “mini-library” of 
sensor variants results in sensors with varying heme-binding stoichiometries, ~5–15 and heme 
dissociation constants, 0.05–0.25 μM. Using these sensors in the malaria parasite, it was found that P. 
falciparum maintains the cytosolic labile heme pool at ~1.6 μM throughout its development in red 
blood cells. Further, it was found that anti-malarial drugs that target heme homeostatic mechanisms 
in P. falciparum, including chloroquine, significantly increase labile heme. Altogether, the advent of 
ratiometric fluorescent heme sensors has greatly expanded the tools available to probe heme 
homeostatic mechanisms and mobilization dynamics in health and disease in an unprecedented 
manner. 
However, one potential drawback with the aforementioned heme sensors is that their 
expression may itself perturb heme homeostasis due to heme sequestration [2]. Moreover, different 
sensor scaffolds may access different heme pools due to kinetic constraints associated with heme 
exchange. Thus, measurements of labile or bioavailable heme may in effect be a sensor-dependent 
parameter. Due to these potential issues, measurements of bioavailable heme with heme sensors can 
be complemented by label-free heme imaging modalities that exploit the rich electronic and 
vibrational transitions of metalloporphyrins, including resonance Raman, photothermal lens and 
transient absorption microscopies (Table 2). Resonance Raman is a vibrational spectroscopy in 
which incident radiation from a laser that is resonant with an electronic transition of a target 
molecule is inelastically scattered upon excitation of various vibrational transitions [248]. The 
difference in energy of the incident radiation and the scattered photons is diagnostic of the specific 
molecules being excited and their local environment. In particular, resonance Raman has been used 
for decades to characterize the coordination environment of heme in various hemoproteins. In 
resonance Raman microscopy, resonance Raman spectroscopy is coupled with microscope optics to 
generate a “Raman map” that gives structural and chemical information with spatial resolution 
[249]. This method has been utilized to probe the activity of a number of hemoproteins in living cells, 
including NADPH oxidase activity in neutrophils and hemoglobin oxygenation in erythrocytes. 
Moreover, it was used to probe hemoglobin and hemozoin distribution during erythrocyte infection 
with P. falciparum [250].  
Photothermal microscopy relies on the detection of local heating generated by optical 
absorption of molecules. When combined with two-photon excitation using longer wavelength light 
to excite a chromophore rather than one-photon linear absorption, there is a decrease in scatter, 
background signal and photo-bleaching with increased sample penetration depth. Heme is an ideal 
candidate for the use of two-photon photothermal lens microscopy as it absorbs strongly and is not 
fluorescent [251,252]. Using photo-thermal lens microscopy, the distribution of hemoproteins, 
including globins and cytochromes, in cell and tissue samples was measured in situ.  
Transient absorption microscopy (TAM) utilizes ultra-fast pulsed lasers to measure the excited 
state dynamics and spatial distribution of chromophores [253]. A “pump” laser is used to excite an 
absorbing species and a “probe” laser is used to measure the excited state dynamics of that molecule. 
The excited state dynamics are diagnostic of particular chromophores and can reveal the chemical 
nature and environment of a molecule [254]. Transient absorption microscopy is efficient at 
quantifying and visualizing chromophores, especially those that have low quantum yields [255]. 
TAM has been utilized to observe heme in frozen heart tissues as well as heme distribution and 
dynamics in C. elegans [253,256]. 
The major advantage of these methods is that samples do not need to be derivatized or 
genetically altered and heme can be probed in situ, ensuring that heme homeostasis and cellular 
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metabolism is not perturbed. However, a limitation is that the spectroscopic features being probed 
may be derived from a complex heterogeneous mixture of heme species, making the deconvolution 
and interpretation of signal changes challenging. On the other hand, in cell types where the signal is 
dominated by a few abundant and/or highly absorbing heme complexes, e.g., hemoglobin in red 
blood cells, the application of such label-free techniques may be simpler to interpret. Altogether, the 
new heme sensors and label-free imaging of heme provide a new set of tools to further define the 
exciting questions related to heme trafficking in living intact cells. 
7. Concluding Remarks 
Heme is a versatile biological molecule of paramount importance for cellular physiology. 
Because of its involvement in virtually all aspects of aerobic life and high relevance to human health 
and pathology, this fascinating metallo-organic compound and its complex metabolism have been 
extensively studied. In spite of over six decades of heme research, many gaps in our understanding 
of cellular heme metabolism still remain. For example, the mechanisms that heme b uses to shuttle 
away from FECH and to route to its sites of utilization across the cell are only beginning to emerge. 
Development of novel models, tools and methods to quantitatively study trafficking of heme and its 
precursors in vivo is highly promising and likely will continue gaining some exciting new insights 
into the mechanisms behind heme transport and distribution within eukaryotic cells. Deciphering 
how heme is routed within and outside mitochondria as well as regulatory aspects of these 
processes will provide answers to a number of outstanding biological questions and contribute 
towards greater understanding of highly prevalent heme-related pathologies. 
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